Total Payments
$151,381
2024 Payments
$1,804
Companies
73
Transactions
736
Medicare Patients
32,296
Medicare Billing
$13.9M
Payment Breakdown by Category
Research$134,773 (89.0%)
Food & Beverage$12,689 (8.4%)
Consulting$3,500 (2.3%)
Travel$302.35 (0.2%)
Education$115.89 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $134,773 | 6 | 89.0% |
| Food and Beverage | $12,689 | 718 | 8.4% |
| Consulting Fee | $3,500 | 3 | 2.3% |
| Travel and Lodging | $302.35 | 2 | 0.2% |
| Education | $115.89 | 7 | 0.1% |
Payments by Type
Research
$134,773
6 transactions
General
$16,607
730 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $125,972 | 1 | $0 (2019) |
| Eli Lilly and Company | $8,851 | 5 | $0 (2019) |
| Celgene Corporation | $2,316 | 26 | $0 (2024) |
| TESARO, Inc. | $2,139 | 7 | $0 (2018) |
| Merck Sharp & Dohme LLC | $1,415 | 91 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,254 | 68 | $0 (2024) |
| Genentech USA, Inc. | $1,068 | 74 | $0 (2023) |
| Janssen Biotech, Inc. | $524.00 | 31 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $523.23 | 28 | $0 (2023) |
| PFIZER INC. | $476.30 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,804 | 85 | Gilead Sciences, Inc. ($200.53) |
| 2023 | $1,471 | 72 | Pharmacyclics LLC, An AbbVie Company ($150.73) |
| 2022 | $1,829 | 98 | Merck Sharp & Dohme LLC ($217.56) |
| 2021 | $1,423 | 88 | Novartis Pharmaceuticals Corporation ($165.41) |
| 2020 | $901.04 | 51 | Merck Sharp & Dohme Corporation ($179.27) |
| 2019 | $127,757 | 99 | Janssen Research & Development, LLC ($125,972) |
| 2018 | $11,280 | 110 | Eli Lilly and Company ($8,667) |
| 2017 | $4,915 | 133 | Celgene Corporation ($2,040) |
All Payment Transactions
736 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.59 | General |
| 12/17/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Oncology | ||||||
| 11/18/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $1.83 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Oncology | ||||||
| 11/11/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $32.40 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/31/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.24 | General |
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: Oncology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $20.94 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.04 | General |
| 10/16/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $34.00 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.42 | General |
| 09/25/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.39 | General |
| 09/19/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $31.45 | General |
| Category: Oncology | ||||||
| 09/05/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Hematology | ||||||
| 09/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | Janssen Research & Development, LLC | $125,972 | 1 |
| MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A CDK4 6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $8,015 | 1 |
| A RANDOMIZED PHASE 3 STUDY OF LY2835219 PLUS BEST SUPPORTIVE CARE VERSUS ERLOTINIB PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH STAGE IV NSCLC WITH A DETECTABLE KRAS MUTATION WHO HAVE PROGRESSED AFTER PLATINUM BASED CHEMOTHERAPY | Eli Lilly and Company | $462.00 | 1 |
| A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | Eli Lilly and Company | $190.25 | 1 |
| RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN | Eli Lilly and Company | $84.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 77 | 6,629 | 121,815 | $17.2M | $4.6M |
| 2022 | 99 | 9,452 | 178,970 | $18.2M | $4.7M |
| 2021 | 88 | 8,422 | 163,963 | $11.7M | $2.5M |
| 2020 | 77 | 7,793 | 186,742 | $10.1M | $2.1M |
Total Patients
32,296
Total Services
651,490
Medicare Billing
$13.9M
Procedure Codes
341
All Medicare Procedures & Services
341 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie | Office | 2023 | 25 | 11,481 | $8.5M | $2.8M | 32.7% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 24 | 23,800 | $4.1M | $976,601 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 639 | 2,020 | $844,138 | $179,427 | 21.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 52 | 9,600 | $714,720 | $167,943 | 23.5% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 38 | 146 | $308,761 | $47,363 | 15.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 100 | 515 | $303,268 | $45,910 | 15.1% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 13 | 5,880 | $192,276 | $43,967 | 22.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 26 | 2,600 | $206,700 | $39,308 | 19.0% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 15 | 504 | $321,104 | $38,528 | 12.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 325 | 511 | $144,373 | $30,896 | 21.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 28 | 3,990 | $166,902 | $22,062 | 13.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 108 | 108 | $76,610 | $16,104 | 21.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 79 | 107 | $120,195 | $16,089 | 13.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 628 | 2,056 | $78,889 | $15,490 | 19.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 614 | 1,809 | $24,313 | $15,113 | 62.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 45 | 36,210 | $126,735 | $13,870 | 10.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 85 | 661 | $156,631 | $13,157 | 8.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 80 | 98 | $48,466 | $12,165 | 25.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 369 | 921 | $61,053 | $9,511 | 15.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 77 | 211 | $61,030 | $9,262 | 15.2% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 19 | 529 | $73,457 | $8,007 | 10.9% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 73 | 101 | $75,451 | $7,684 | 10.2% |
| 79101 | Radioactive drug therapy through a vein | Office | 2023 | 30 | 68 | $31,165 | $6,343 | 20.4% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 378 | 979 | $29,184 | $5,783 | 19.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 41 | 128 | $32,502 | $5,559 | 17.1% |
About Dr. Petros Nikolinakos, M.D
Dr. Petros Nikolinakos, M.D is a Internal Medicine healthcare provider based in Athens, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2007. The National Provider Identifier (NPI) number assigned to this provider is 1306041900.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Petros Nikolinakos, M.D has received a total of $151,381 in payments from pharmaceutical and medical device companies, with $1,804 received in 2024. These payments were reported across 736 transactions from 73 companies. The most common payment nature is "" ($134,773).
As a Medicare-enrolled provider, Nikolinakos has provided services to 32,296 Medicare beneficiaries, totaling 651,490 services with total Medicare billing of $13.9M. Data is available for 4 years (2020–2023), covering 341 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Athens, GA
- Active Since 06/15/2007
- Last Updated 07/19/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1306041900
Products in Payments
- Abraxane (Drug) $1,985
- ZEJULA (Drug) $1,163
- KEYTRUDA (Biological) $1,114
- VARUBI (Drug) $1,015
- IMBRUVICA (Drug) $525.11
- MEKINIST (Drug) $318.11
- DARZALEX (Biological) $309.06
- TECENTRIQ (Biological) $289.94
- Orserdu (Drug) $265.26
- Lenvima (Drug) $261.66
- LIBTAYO (Biological) $243.79
- XTANDI (Drug) $192.04
- TAZVERIK (Drug) $187.93
- Tavalisse (Drug) $183.58
- TASIGNA (Drug) $180.42
- CYRAMZA (Drug) $177.31
- ADCETRIS (Biological) $175.89
- Perjeta (Biological) $169.92
- IBRANCE (Drug) $167.02
- Enhertu (Drug) $164.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Athens
Dr. Catherine Marti, Md, MD
Internal Medicine — Payments: $295,383
Internal Medicine $295,383
Kent Nilsson, M.d, M.D
Internal Medicine — Payments: $175,364
Internal Medicine $175,364
Karan Julka, Md, MD
Internal Medicine — Payments: $69,118
Internal Medicine $69,118
Antonio Sotolongo, M.d, M.D
Internal Medicine — Payments: $47,039
Internal Medicine $47,039
Asif Qadri, M.d, M.D
Internal Medicine — Payments: $46,806
Internal Medicine $46,806
Maurice Alston, D.o, D.O
Internal Medicine — Payments: $36,398
Internal Medicine $36,398